Short answer: Cordyceps militaris is neither a proven “ATP factory” nor a supplement I currently recommend in France. Human endurance trials are few, heterogeneous and sometimes conducted with blends. Above all, the European Commission’s Novel Food catalogue classifies its mycelium and fruiting body as a novel food not yet authorised.
The sales pitch is polished: cordycepin “resembles adenosine”, so the mushroom “recharges your ATP”. This is pure Mitochondria Marketing: a real mechanism turned into a performance promise that human trials do not confirm. The mushroom’s scientific interest is worth discussing. It must not be used to sidestep its regulatory status.
The status of Cordyceps militaris in the European Union
The official catalogue links entry POL-NF-09242 to Cordyceps militaris. It specifies that the entry covers the mycelium and fruiting body, both classified as “Not yet authorised novel food”.
The catalogue is a guidance tool, not an individual legal ruling. It states that the operator must be able to demonstrate a history of significant food consumption in the Union before 15 May 1997 or hold an applicable Novel Food authorisation. In cases of doubt, consultation with the national authority is provided for.
The binding framework comes notably from Regulation (EU) 2015/2283. Article 6 states that only novel foods authorised and included on the Union list may be placed on the market or used in foods under the specified conditions.
The practical consequence is simple: a box being listed on a marketplace does not prove compliance. Without an identifiable authorisation covering the preparation being sold, buying or recommending C. militaris as a supplement in France is not a prudent decision.
This may change. Its status should therefore be checked in the catalogue and the Union list at the time of purchase, not inferred from an old article or a commercial claim.
A future authorisation would change whether a defined preparation could be marketed, not automatically our verdict on efficacy. A Novel Food authorisation assesses, among other things, safety under specified conditions. It does not turn the product into a treatment or guarantee improved sports performance. You would still need to check that the product exactly matches the authorised specifications and that a human trial characterises the same species, part, extract and dose. Regulation, quality and efficacy are three distinct filters and must be documented separately for each preparation.
Cordyceps militaris and Ophiocordyceps sinensis are not interchangeable
The word “Cordyceps” covers several products that differ in species, part and processing method:
- Cordyceps militaris is a cultivable species that produces cordycepin, among other compounds
- Ophiocordyceps sinensis, formerly Cordyceps sinensis, refers to the species historically associated with a larva in the Asian highlands
- CS-4 is a mycelial fermentation preparation used in some trials, not the whole wild complex
- a fruiting body extract and mycelial biomass do not necessarily have the same chemical profile
The European catalogue currently classifies the mycelium and fruiting body of O. sinensis as non-novel in food supplements. This designation is limited to supplements. It is neither a medical authorisation, nor confirmation of efficacy, nor blanket permission for all food categories.
The shortcut “a study on Cordyceps validates all Cordyceps” is therefore wrong. The study must match the product’s species, strain, part, extraction method and dose.
Cordycepin and ATP: the marketing mechanism does not hold up
Cordycepin is 3’-deoxyadenosine. It resembles adenosine, but this structural similarity does not mean it becomes a building block that automatically produces more ATP.
In cell and animal models, cordycepin influences several pathways related to metabolism, inflammation and RNA synthesis. A study often used to claim that C. militaris “increases ATP” administered an extract to animals and measured biomarkers associated with energy production. It does not demonstrate an increase in available ATP in a human athlete.
Three levels of evidence are routinely confused:
- the presence of a compound similar to adenosine
- a change in energy markers in animals
- a reproducible improvement in human performance
Only the third level answers the athlete’s question. Yet the human evidence remains weak.
What the VO2 max trials really show
The 2017 blend containing C. militaris
The most frequently cited trial included 28 young adults and compared 4 g per day of a mushroom blend containing C. militaris with a placebo. After one week, no significant effect was observed on VO2 max, ventilatory threshold, time to exhaustion or power output.
Only ten volunteers continued for another two weeks. In this small subgroup, the authors observed a favourable signal for VO2 max and certain exercise parameters. This finding can generate a hypothesis. It cannot establish that the effect was due to C. militaris alone or define an effective dose.
The 2026 acute trial
A randomised crossover trial published in 2026 tested an acute dose of 1 g of standardised extract in twelve young, active men, thirty minutes before a maximal cycling test. The extract did not change peak VO2, heart rate, blood pressure or blood glucose compared with placebo.
Faster reaction time was observed after exercise, but the treatment-by-time interaction was not significant. With twelve participants and numerous outcomes, this cognitive signal must remain exploratory.
CS-4 trials do not validate C. militaris
In 20 adults aged 50 to 75, 1 g per day of CS-4 for twelve weeks increased metabolic and ventilatory thresholds. VO2 max did not change. In 22 trained cyclists, 3 g per day for five weeks improved neither peak VO2, ventilatory threshold nor time-trial performance.
These conflicting results concern a different preparation. Above all, they show that training level, duration and product influence results.
The human evidence review in 2026
A 2026 narrative review identified five intervention studies on C. militaris, involving a total of 321 participants aged 16 to 35. Protocols ranged from 1 to 16 weeks and from 1 to 12 g per day. Some studies used the mushroom alone, others used multi-ingredient formulas.
The authors consider the results inconsistent. They highlight several limitations:
- small samples
- heterogeneous participants and exercise tests
- insufficiently described randomisation in several studies
- frequent lack of preregistration
- preparations not standardised for bioactive compounds
- use of blends preventing isolation of the mushroom’s effect
The right conclusion is therefore not “it never works”. Rather: we do not know which preparation provides a meaningful benefit, for whom, or how large that benefit is.
Fatigue, cognition, blood glucose and recovery
The promises often go beyond endurance. C. militaris is presented as a solution for brain fog, muscle soreness, lactic acid or blood glucose fluctuations. These claims mainly rest on mechanisms, animal studies or secondary measurements.
No robust evidence shows that an extract treats persistent fatigue in a healthy person. New or lasting fatigue can signal insufficient sleep, a deficiency, an infection, a thyroid disorder, sleep apnoea, a medication effect or a disease. Masking it with a supplement can delay a useful assessment.
For recovery, inflammatory markers or creatine kinase are not equivalent to less pain, a faster return to training or better performance in the next session.
Why we no longer give a dose or timing
Forum advice suggesting 1 to 3 g taken 45 to 60 minutes before exercise gives unjustified precision. Studies use products that differ too much to establish a universal dose. Its European status also makes practical recommendations inappropriate.
There is no evidence that the effect reaches a useful “plasma peak” 45 minutes after taking a commercial powder, or that a cycle of five days on and two days off limits tolerance. These protocols came from forum habits, not comparative trials.
If you already own a product, the minimum checks are as follows:
- do not consume it until the species and the preparation’s status have been established
- ask the seller for the Latin name, part, processing method and European regulatory basis
- do not accept “registered with the DGCCRF” as proof of Novel Food authorisation
- keep the label and batch number in case of an adverse reaction
Administrative registration of a supplement and Novel Food authorisation answer two different questions.
Risks and interactions
Human trials are too short to establish the safety of prolonged consumption. Digestive problems, dry mouth or allergic reactions may occur with fungal products. Actual composition, contaminants and species substitutions also pose quality risks.
Ask a doctor or pharmacist for advice before taking any Cordyceps-related product if you take an anticoagulant, an antidiabetic drug, an immunosuppressant or cancer treatment. Caution is also needed during pregnancy, breastfeeding, before surgery, in minors and in cases of liver, kidney, autoimmune or blood disease.
Stop taking it and seek medical advice promptly if you experience breathing difficulties, swelling, a widespread rash, jaundice, dark urine, unusual bleeding or feel seriously unwell.
Legal, better-supported alternatives for VO2 max
To improve VO2 max · FR, training produces a much stronger signal than a mushroom. A simple strategy combines:
- two to three easy endurance sessions per week, adapted to your level
- one sufficiently intense interval session, with gradual progression
- recovery and energy intake suited to the training load
- a standardised test every four to eight weeks
Le Zone 2 cardio builds the aerobic base. Intervals provide a greater stimulus for maximal aerobic power. If your performance drops despite a coherent programme, first look at sleep, energy availability, iron, training load and a possible medical cause.
The Verdict
Cordyceps militaris remains scientifically interesting, particularly because of its cordycepin. But biological plausibility does not replace a reproducible clinical effect. Human trials do not demonstrate a reliable increase in VO2 max, ATP or recovery with a standard preparation.
In August 2026, its European status alone settles the practical decision: I do not recommend buying it, taking any dose or using a stack based on C. militaris. Ophiocordyceps sinensis has a different status in supplements, but its results are no easier to generalise.
The right move is not to look for another seller of C. militaris. It is to demand exact identification, a match with the trials and a clear regulatory basis before turning an appealing mechanism into a routine.
The Mush’N’Go alternative worth knowing about
Mush’N’Go still lists “Cordyceps” in Brainstoorm, but the technical document published by the brand identifies it as Cordyceps sinensis, now Ophiocordyceps sinensis. So it is not the C. militaris advised against in this article.
This difference does not prove a gain in VO2 max. It does, however, make Brainstoorm a more suitable choice for someone looking for a low-caffeine mushroom drink rather than a sports-focused C. militaris extract. Our recommendation is based on the all-in-one format and the stated 20 mg of caffeine.
Partner alternative to C. militaris
Brainstoorm, code JEY: -15%
The brand documents its Cordyceps as C. sinensis. The code brings the price of 30 servings down to €33.92.
Discover Brainstoorm with code JEY
Partner link. This alternative is not presented as a product that improves VO2 max.
